Source: Cardiovascular Business, by Michael Walter

Hydroxychloroquine is not associated with an abnormal amount of arrhythmic events among COVID-19 patients, according to a brand new analysis out of Europe.

The study, published in EP Europace, includes data from 649 COVID-19 patients treated with the drug. All patients were enrolled from March 10 to April 10, 2020, and the most common symptoms were fever, dry cough and dyspnea. Patients were treated in a variety of clinical settings, including ICUs, medical wards and even at home. While 53.8% of patients were given hydroxychloroquine alone, 30% of patients received two QT-prolonging drugs in total. Another 13.6% of patients received three QT-prolonging drugs.

Overall, the authors said hydroxychloroquine was only associated with “modest QTc prolongation.” The overall major ventricular arrhythmia rate was just 1.1%. From their perspective—they were specifically focused on its arrhythmic safety—the medication “seems to be safe, regardless of the clinical setting in which it is started” as long as an adequate ECG monitoring strategy is in place.

The team emphasized that it was not ruling on the overall “clinical efficacy” of hydroxychloroquine with this research.

“In order to draw definitive conclusions regarding the impact of hydroxychloroquine on COVID-19 patients, results from one of the several ongoing trials are needed,” wrote lead author Alessio Gasperetti, MD, of the Heart Rhythm Center in Milan, Italy, and colleagues. “On the other hand, this study aims to present the available data regarding the hydroxychloroquine arrhythmic safety profile in COVID-19 patients, to provide physicians with real-world evidence coming from three different clinical settings, upon which to build a more evidence-based decision-making process.”

Of all the potential COVID-19 treatments discussed throughout the last several months, none have grabbed more mainstream attention than hydroxychloroquine.

Click here to read the full EP Europace study.






Related:

Belgium Study 8,075 patients: Low HCQ doses resulted in lower mortality in Covid patients

Italy Study 3,451 patients: Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study

How hydroxychloroquine works at the cellular level

Why Is The Media Suppressing Information About Hydroxychloroquine’s Effectiveness Against COVID?

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »

The Chloroquine Wars Part XIV – How to Rig Research: Surgisphere Part I

It was in these very moments in late May when public health officials lost all credibility—a credibility that cannot be restored without major changes taking place. Despite most evidence pointing to a likelihood of HCQ efficacy, they made their call on the back of data supposedly tucked away in a database that nobody had verified, declared it definitive, then swiftly pushed for policy changes around the world.

Read More »

Another New York State Supreme Court Justice Ivermectin Order Helping 81-Year-Old Farmer

Ivermectin, a medicine for parasites, has been around for four decades. While not authorized for use against COVID-19, dozens of studies show materially positive results. At well-established human dosage levels, the drug is safe: hundreds of millions of people are treated with it every year mostly in the tropics for various parasite-borne diseases, such as River Blindness in Nigeria.

Read More »

The Chloroquine Wars Part XIII -A Clockwork Orange Man

Immediately following HCQ’s Trump moment, the media went on an all-out blitz to associate the topic of HCQ with a sense of fear. Fear of Trump, fear of death, fear of incompetence, fear of opposing scientific authorities, fear of using medicine needed by somebody else, and fear of the unknown. And the campaign of fear didn’t stop there.

Read More »